Ratings by Guggenheim (Debjit Chattopadhyay)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
1/18/2024 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Buy (N/A) |
16.75 (22.49) |
34.27% | Details | |
12/21/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
12/21/2023 | Soleno Therapeutics Inc. | SLNO | Maintain | Buy (N/A) |
|
Details | ||
12/21/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
11/21/2023 | Soleno Therapeutics Inc. | SLNO | New Coverage | Buy (N/A) |
27.96 (42.87) |
53.33% | Details | |
8/14/2023 | Centessa Pharmaceuticals | CNTA | Maintain | Buy (N/A) |
|
Details | ||
7/31/2023 | Prime Medicine | PRME | New Coverage | Buy (N/A) |
14.84 (6.81) |
-54.11% | Details | |
6/12/2023 | Centessa Pharmaceuticals | CNTA | New Coverage | Buy (N/A) |
4.61 (10.99) |
138.39% | Details | |
1/26/2023 | Dyne Therapeutics | DYN | New Coverage | Buy (N/A) |
13.51 (27.96) |
106.96% | Details | |
10/13/2022 | Ultragenyx Pharma | RARE | Upgrade | Buy (Neutral) |
38.47 (46.72) |
21.45% | Details | |
6/27/2022 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Buy) |
147.50 (153.24) |
3.89% | Details | |
5/2/2022 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
4/5/2022 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
3/1/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
33.38 (44.56) |
33.49% | Details | |
3/1/2022 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
2/25/2022 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
2/24/2022 | Intellia Therapeutics | NTLA | Maintain | Buy (N/A) |
|
Details | ||
2/3/2022 | Alnylam Pharmaceuticals | ALNY | Upgrade | Buy (Neutral) |
145.26 (153.24) |
5.49% | Details | |
1/5/2022 | Beam Therapeutics Inc | BEAM | New Coverage | Buy (N/A) |
78.31 (33.96) |
-56.63% | Details | |
12/16/2021 | Taysha Gene Therapies | TSHA | New Coverage | Buy (N/A) |
14.24 (3.19) |
-77.6% | Details | |
12/1/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
10/5/2021 | Intellia Therapeutics | NTLA | New Coverage | (N/A) |
126.78 (26.90) |
-78.78% | Details | |
7/15/2021 | Ultragenyx Pharma | RARE | New Coverage | Neutral (N/A) |
84.74 (38.47) |
-54.6% | Details | |
5/6/2021 | Freeline | FRLN | New Coverage | Buy (N/A) |
11.25 (6.48) |
-42.4% | Details | |
1/7/2021 | Sangamo BioSciences | SGMO | New Coverage | Neutral (N/A) |
16.01 (0.63) |
-96.06% | Details | |
1/6/2021 | uniQure BV | QURE | Upgrade | Buy (Neutral) |
37.77 (5.34) |
-85.86% | Details |